First results of the clinical trial with L19-IL2 in combination with Dacarbazine for the treatment of melanoma are presented at ASCO by B. Weide, T.K. Eigentler, A. Romanini, F. de Braud, V. Lovato, E. Trachsel, L. Giovannoni, D. Neri, H.D.Menssen, C. Garbe.
(Abstract "Tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with dacarbazine in patients with advanced melanoma").

Philogen is invited to present its pipeline at the GEM Partnering Event organized by Roche in Paris on 23 June 2010.

The results of the first clinical trial with 131I-L19 are presented at ASCO on June 5 by G. Del Conte, P. Erba, A. Fasolo, C. Chiesa, C.M. Grana, H.D. Menssen, D. Neri, G. Mariani, E. Bambardieri, L. Gianni.
(Abstract "Radioimmunotherapy (RIT) with 131I-L19SIP in solid cancers and lymphoproliferelative diseases: final results of the first human trial").

Philogen will present at the UBS Global Specialty Pharmaceuticals Conference, 2-3 June 2010, London.

Philogen is present at the Bio International Convention in Chicago (May 3-6) with an exhibition booth (n° 2464). The Director of Business Development will represent the company.

Philogen is present at the Bio-Europe Spring 2010 (Barcellona, Spain) with an exhibition booth. The Director of Business Development will represent the company.

Philogen announces the acquisition of a biologics production facility located in Rosia (Italy) in the vicinity of Siena. The facility was recently vacated by Bayer and is adjacent to the one of the largest Novartis vaccine production sites. The new plant includes office space and laboratories of 2.600 square meters, and expansion space of approximately 3 hectares.